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4200-319 Porto, Portugal
5 Institute for Molecular Cell Biology, Universidade do Porto (IBMC), Rua do Campo Alegre 823, 4150-180 Porto, Portugal
6 Faculty of Biotechnology, Catholic University of Porto, Rua Dr. António Bernardino de Almeida 400, 4200-072 Porto, Portugal
Correspondence should be addressed to Inês Campos Costa; inescamposcostamd@gmail.com
Received 5 July 2013; Revised 20 August 2013; Accepted 5 September 2013
Academic Editor: Antonio Aversa
Copyright © 2013 Inês Campos Costa et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Erectile dysfunction (ED), metabolic syndrome (MetS), and hypogonadism are closely related, often coexisting in the aging male.
Obesity was shown to raise the risk of ED and hypogonadism, as well as other endocrinological disturbances with impact on erectile
function.We selected 179 patients referred for ED to our andrology unit, aiming to evaluate gonadotropins and estradiol interplay in
context of ED,MetS, and hypogonadism. Patientswere stratified into groups in accordancewith the presence (or not) ofMetS and/or
hypogonadism. Noticeable differences in total testosterone (TT) and free testosterone (FT) levels were found between patients with
and without MetS. Men withMetS evidenced lower TT circulating levels with an increasing number of MetS parameters, for which
hypertriglyceridemia and waist circumference strongly contributed. Regarding the hypothalamic-pituitary-gonadal axis, patients
with hypogonadism did not exhibit raised LH levels. Interestingly, among those with higher LH levels, estradiol values were also
increased. Possible explanations for this unexpected profile of estradiol may be the age-related adiposity, other estrogen-raising
pathways, or even unknownmechanisms. Estradiol is possibly amolecule with further interactions beyond the currently described.
Our results further enlighten this still unclear multidisciplinary and complex subject, raising new investigational opportunities.
1. Introduction
Erectile dysfunction (ED) is the persistent inability to attain
and/or maintain an erection of sufficient rigidity for sexual
intercourse. Its prevalence has a tendency to increase over
time [1], being expected a worldwide increase of 12.0% from
1995 to 2025 [2]. An observational study revealed that 12.9%
of Portuguese men suffer from ED, with 5.8% describing it as
moderate/severe, and that ED was most prevalent amongst
men over the age of 60 [3]. ED has been linked to metabolic
syndrome (MetS) [4], which is an assembly of cardiova-
scular (CV) and metabolic risk factors, such as visceral adi-
posity, insulin resistance/diabetes, high blood pressure, and
dyslipidemia. Although several definitions of MetS have
been devised, the one proposed by the National Cholesterol
Education Program-Adult Treatment Panel III [5] emerged
as the most widely used definition, due to its simplicity
and superiority as a predictor of secondary outcomes. Its
prevalence in Portuguesemale population is 18.7% [6], which
is superior to other European countries [7].
Aging and age-related comorbidities are strongly associ-
ated with the increased prevalence of ED [1, 8], MetS [6],
and hypogonadism [7]. All these conditions often coexist
in the same patient [9, 10], whilst hypogonadism and ED
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have been demonstrated to increase the risk of MetS [9, 11–
15], supporting the idea of a multifactorial/directional endo-
crinological imbalance that occurs in specific subsets of
ED patients. Elderly men are prone to develop late onset
hypogonadism (LOH), a condition characterized by a pro-
gressive testicular impairment associated with specific sexual
symptoms (amongst them, ED) and a deficiency of serum T
levels [16, 17]. Several studies support LOH, unveiling that T
levels decrease along aging [14, 16, 18, 19].
Obesity by itself contributes to a wide range of endocrine
disturbances, such as reduced T levels. Indeed, among ED
patients, obese men present lower T levels compared to
those observed in the elder [15]. One of the most plausible
mechanisms by which obesity contributes to T levels decline
is the adipose tissue dependent aromatization of T to estradiol
[15]. In line with these remarks, hormonal ED etiology might
not be confined to androgen deficiency, as isolated high
estradiol levels have been reported in some ED patients [8,
20].
In addition to sexual hormones disturbances, several
other endocrinological imbalances might be found in ED
patients. ED has been related with glandular anomalies,
such as hyper- and hypothyroidism [21, 22]. However, the
relationship between the latter and ED is still controversial
[21–23]. Nonetheless, it is unlikely that ED associated with
hyperthyroidism is owed to hypogonadism, as no thyroid
hormone-dependent alteration in calculated free testosterone
(FT) levels has been described [21]. Severe hyperprolactine-
mia has been also reported as a cause of ED, since it may
compromise sexual desire and inhibit T secretion [22, 24],
an outcome that is potentially reversible by treating the
underlying disorder [24].
Hypogonadism and MetS strongly increase the risk of
ED at any age and both are risk factors for CV disease
[9, 25–27]. From several studies in this area, the importance
of understanding the complex interactions between those
entities became clear, as well as the underlying modulating
factors. In this study, we describe the hormonal milieu of
a Portuguese population with ED, comparing MetS to non-
MetS groups and correlating T levels with the number of
MetS parameters. Moreover, we analyze the hypothalamic-
pituitary-gonadal (HPG) axis in ED patients with and with-
out hypogonadism, aiming to describe and evaluate nonex-
pected hormonal alterations in this axis and further uncover
the relation between these three increasingly prevalent
conditions.
2. Materials and Methods
We selected 179 Caucasian patients referred to our andrology
unit for ED between January 2008 and March 2012. All
of them gave their written informed consent and had a
complete hormone assessment available. A known history
of neurological disease, pelvic trauma, major psychiatric
disorder, hepatic failure, end-stage renal disease, or drug
abuse was an exclusion criterion. A standardized health
questionnaire covering medical anamnesis (including sex-
ual history), CV risk factors, smoking and alcohol intake
history and current medication was obtained. All patients
underwent a standardized physical examination protocol.
Anthropometric evaluation, including weight, height, and
waist circumference (WC), was acquired by the same tech-
nician with the subjects in light clothing and barefoot. Blood
pressure was measured in the right arm using an automatic
manometer (DINAMAP Procare 300, GE, UK) in the sit-
ting position after a 10-minute rest period. Blood analysis
was performed using samples of venous blood collected
between 8:00 and 10:00 a.m., after a 12-hour overnight fasting
period.
The following measurements were made by routine lab-
oratory methods: triglycerides (Trig), high-density lipopro-
tein cholesterol (HDL), low-density lipoprotein cholesterol
(LDL), total cholesterol, serum glucose, and albumin. Total
testosterone (TT), sex hormone-binding globulin (SHBG),
estradiol, prolactin, follicle-stimulating hormone (FSH),
luteinizing hormone (LH), and insulin were determined by
chemiluminescencewith a commercially available kit (Cobas;
Roche Diagnosis GmbH, Manheim, Germany). Triiodothy-
ronine (T3), thyroxine (T4), and thyroid-stimulating hor-
mone (TSH) were determined by chemiluminescence with
a commercially available kit (Abbott Diagnostics Division,
Princeton, NJ, USA). Free testosterone was calculated using
the Free and Bioavailable Testosterone calculator, developed at
theHormonologyDepartment, UniversityHospital of Ghent,
Belgium (http://www.issam.ch/freetesto.htm).The electronic
process of each patient and available digitalized records
were also consulted. Body mass index (BMI) was calculated
based on weight in kilograms and height in meters (kg/m2).
Participants were considered obese if BMI was ≥30 kg/m2.
The presence of three ormore of the following criteria defined
MetS, according to NCEP-ATPIII (2002): central obesity
(WC >102 cm), hypertriglyceridemia (Trig ≥150mg/dL or
treatment), low HDL cholesterol (<40mg/dL or treatment),
hypertension (HT, blood pressure ≥130/85mmHg or treat-
ment), and fasting serum glucose ≥110mg/dL [5]. Hypogo-
nadismwas defined as TTbelow 3.50 ng/mL (11.10 nmol/L) or
calculated FTbelow 0.072 ng/mL [28].We considered normal
LH levels between the normal range of 1.70 to 8.60 mUI/mL.
Hypothyroidism was defined as TSH levels >4.94 𝜇U/mL
and T4 levels in the normal range or <0.70 ng/dL. Hyper-
thyroidism was defined as TSH levels <0.35 𝜇U/mL, T3
levels >3.71 pg/mL, and T4 levels >1.48 ng/dL. Hypo- and
hyperinsulinemia were considered at insulin levels inferior to
2.60 𝜇U/mL and superior to 24.90𝜇U/mL, respectively.
2.1. Statistical Analysis. Absolute and relative frequencies
were used to describe categorical variables as well as median
and percentiles 25 and 75 were applied in the description of
continuous variables.Chi-square andKruskal-Wallis tests were used to evaluate
the differences between the subgroups with and without
MetS, respectively, for categorical and continuous variables.
We considered the differences statisticaly significant when
𝑃 < 0.050.
All data analyses were performed using STATA software,
version 9.2.
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Table 1: Population characteristics.
All participants
(𝑛 = 151)








Age (years), median (P25–P75) 56.0 (50.0–62.0) 56.0 (52.0–62.0) 58.0 (48.0–62.0) 0.790
Weight (kg), median (P25–P75) 80.0 (72.0–86.0) 82.0 (77.0–94.0) 75.0 (68.9–83.5) <0.001
Height (cm), median (P25–P75) 179.0 (164.0–173.0) 170.0 (163.0–173.0) 169.0 (164.0–173.0) 0.799
BMI (kg/m2), median (P25–P75) 27.9 (25.2–30.5) 29.7 (27.7–31.4) 26.3 (24.4–28.3) <0.001
Waist circumference (cm), median




median (P25–P75) 4.5 (3.5–5.6) 4.0 (3.2–5.0) 5.1 (4.1–5.9)
0.001
Free calculated testosterone (ng/mL),
median (P25–P75) 0.102 (0.074–0.156) 0.122 (0.074–0.653) 0.093 (0.075–0.113)
<0.001
SHBG (nmol/L), median (P25–P75) 35.8 (27.3–48.6) 33.6 (23.8–41.6) 40.2 (31.4–55.0) 0.003
LH (mUI/mL), median (P25–P75) 4.0 (2.7–5.9) 4.1 (3.1–7.6) 3.7 (2.6–5.4) 0.062
Estradiol (pg/mL), median (P25–P75) 28.5 (22.0–37.8) 26.0 (21.0–35.4) 31.0 (23.2–40.0) 0.164
FSH (mUI/mL), median (P25–P75) 5.0 (3.7–7.3) 5.1 (3.7–8.1) 4.6 (3.5–6.1) 0.164
TSH (𝜇U/mL), median (P25–P75) 1.3 (1.0–1.8) 1.3 (0.9–1.8) 1.3 (1.0–1.7) 0.634
T3 (pg/mL), median (P25–P75) 3.0 (2.8–3.3) 3.0 (2.8–3.3) 3.0 (2.7–3.3) 0.404
T4 (ng/dL), median (P25–P75) 1.0 (0.9–1.1) 1.1 (1.0–1.2) 1.0 (0.9–1.1) 0.040
Comorbidities
Hypogonadism, 𝑛 (%) 35.0 (23.2) 17 (23.0) 18.0 (23.4) 0.953
Hypothyroidism, 𝑛 (%) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) —
Hyperthyroidism, 𝑛 (%) 1.0 (0.6) 0.0 (0.0) 0.0 (0.0) —
Hyperprolactinemia, 𝑛 (%) 183 (8.2) — — —
Alcohol intake, 𝑛 (%)
Absent 70.0 (61.9) 25.0 (67.6) 45.0 (59.2)
0.541Frequent 41.0 (36.3) 12.0 (32.4) 29.0 (38.2)
Former intake 2.0 (1.8) — 2.0 (2.6)
Smoking status, 𝑛 (%)
Never smoked 55.0 (36.7) 25.0 (33.8) 30.0 (39.5)
0.001Smoker 32.0 (21.3) 9.0 (12.2) 23.0 (30.3)
Former intake 63.0 (42.0) 40.0 (54.0) 23 (30.3)
∗Participants with MetS versus participants without MetS.
Data are expressed as the 25th percentile–the 75th percentile (P25–P75).
Metabolic syndrome (MetS), bodymass index (BMI), Sex-hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH),
thyroid-stimulating hormone (TSH), free triiodothyronine (T3), and free thyroxine (T4).
3. Results
From the 179 patients who were engaged in this study, 28
subjects were excluded due to insufficient data. The remai-
ning 151 subjects had a median age, BMI, and WC, respec-
tively, 56 years (P25–P75: 50–62), 27.9 kg/m2 (25.2–30.5), and
104.0 cm (97.0–111.0). Current or past alcohol consumption
was absent in the majority of patients (61.9%), having only
36.8% reported a current frequent intake (until 37 gr of
alcohol per day) and 1.8% history of past intake. Smoking
habits were majorly absent (36.7%) or in the past (42.0%),
having only 21.3% reported being active smokers. Further
population characteristics are contemplated in Table 1.
Concerning the hormonal profile, the median TT, FT,
SHBG, LH, and estradiol levels were 4.5 ng/mL (P25–P75:
3.5–5.6), 0.102 ng/mL (0.074–0.156), 35.8 nmol/L (27.3–48.6),
4.0 ng/mL (2.7–5.9), and 28.5 ng/mL (22.0–37.8), respectively.
Levels of FSH, TSH, T3, and T4 were also measured and are
described in Table 1. Hypothyroidism was not present in any
of the patients, whereas hyperthyroidism was present in one.
Hyperprolactinemia was present in 15 patients (8.2%) and
hyperinsulinemia in 5 (7.4%).

























Figure 1: Box-plot representation showing a statistical significant
decrease of the total testosterone levels (vertical axis) with the
increase of the metabolic syndrome (MetS) parameters (horizontal
axis) (𝑃 < 0.001).
MetS, according to NCEP-ATPIII criteria, was present in
49% of our patients. These patients evidenced significantly
higher calculated FT levels of 0.1225 ng/mL (0.0738–0.6530),
when compared to patients without MetS (𝑃 < 0.001). Conv-
ersely, patients without MetS evidenced median TT of
5.1 ng/mL (4.1–5.9) and median SHBG of 40.2 nmol/L (31.4–
55.0), which were significantly higher in comparison to those
with MetS (𝑃 = 0.001 and 𝑃 = 0.003, resp.). Comparison
measurements are further described in Table 1.
Age, TSH, FSH, and estradiol levels presented no signifi-
cant differences between patients with or without MetS (𝑃 =
0.790, 𝑃 = 0.634, 𝑃 = 0.164, 𝑃 = 0.164, resp.). No differences
were observed in median LH levels between patients with or
without MetS (𝑃 = 0.062).
The relationship between hypogonadism and MetS was
also evaluated. Hypogonadism was present in 23.2% of the
patients, and no differences in its frequency were found
between patients with and without MetS (𝑃 = 0.953). How-
ever, TT levels were decreased consistently with the increase
of the number of parameters of MetS (𝑃 < 0.001) (Figure 1).
Moreover, multivariate regression analysis demonstrated that
within MetS, WC (𝑃 = 0.017) and hypertriglyceridemia
(𝑃 = 0.050) were independently associated with a decrease in
serum T levels. In spite of such observations, the presence of
MetS did seemnot to influenceTT andFT levels amongst pat-
ients with hypogonadism. Multivariate regression analysis
also demonstrated that the MetS is a determinant indepen-
dent of lower TT levels independent of the other model
variables such as age, alcohol consumption, and smoking
habits (beta coefficient:−0.70; 95% confidence interval:−1.29,
−0.10).
The relationship between MetS with LH levels was evalu-
ated and is presented in Table 2. LH levels werewithin normal
range or decreased in 136 patients, regardless of the presence
ofMetS.Moreover, amongst patients with hypogonadism, LH
levels did not vary with the MetS presence (𝑃 = 0.844).
On the other hand, as shown in Figure 2, estradiol lev-
els varied in patients with hypogonadism, which was related








Raised LH levels, 𝑛 (%)
Yes 6.0 (10.7) 0.903 3.0 (5.2) 0.909
No 50.0 (89.3) 55 (94.8)
With hypogonadism
Raised LH levels, 𝑛 (%)
Yes 2.0 (11.8) 0.903 1.0 (5.9) 0.909
No 15.0 (88.2) 16.0 (94.1)
∗Participants with raised LH levels versus participants without raised LH
levels.
LH levels were considered normal from 1.7 to 8.6mUI/mL. Hypothalamic-
pituitary-gonadal (HPG) axis was considered to be disrupted when the LH

















Low/normal LH levels High LH levels
Figure 2: Box-plot representation showing a statistical significant
increase of the estradiol levels (vertical axis) with the increase of the
luteinizing hormone levels (LH) (horizontal axis) (𝑃 = 0.033).
to dissimilarities in LH levels (𝑃 = 0.033). In these patients
with hypogonadism, we characterized the estrogen levels acc-
ording to the axis response (low or normal LH levels versus
raised LH levels). Indeed, while estradiol levels increased, LH
levels were raised (normally functioning axis) and dropped
while the LH levels were normal or low.
4. Discussion
Hypogonadism and MetS are strongly associated [12, 13, 16],
having even been demonstrated that with the increasing
number of MetS parameters there is a proportional raise
in the incidence of hypogonadism [29]. Although hypogo-
nadism was present in 23.2% of our patients, no noticeable
differences were observed among thosewith orwithoutMetS.
In the recent years, several studies unveiled that the
increasing number of MetS components is inversely associ-
ated with T levels [12, 13, 27, 30]. Accordingly, our population
with hypogonadism and MetS showed a decrease in T
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levels with the increase in the number of MetS parameters.
Thus, although the presence of MetS did not prove to be a
significant determinant of hypogonadism, as it did not lead to
a decline in T levels, inMetS patients with already established
hypogonadism, the increasing number of MetS features was
associated with further decline in T.
In the setting of MetS, hypertriglyceridemia and incre-
ased WC have been reported as the most important deter-
minants of hypogonadism [10, 16]. Accordingly, in patients
with MetS, these two features revealed the major influence
on decreasing T levels, with the former being the strongest
independent conditioning factor. In fact, recent literature
consistently associates obesity not only with higher risk of
hypogonadism [4, 6, 27] but also with lower T levels [8].
Visceral adiposity has been particularly related with reduc-
tion of T and SHBG levels (independent of other metabolic
disorders) [15, 27]. In this study, WC was one of the MetS
parameters with the greatest influence in T levels decrease,
presenting itself as a strong risk factor for hypogonadism
development. Furthermore, the metabolic and hormonal
profile of our population is not only consistent with ED
presence but also reinforces the usefulness of MetS screening
for ED and CV disease prevention [9, 25–27].
Aiming to establish further relations amongst the conditi-
ons described above, several authors observed that the MetS-
related T decline was not accompanied by an increase in
pituitary LH levels, suggesting impairment in gonadotropin
secretion [27]. The term mixed hypoandrogenism (primary
and secondary) was proposed for this phenomenon [9, 31].
Themolecules behind this smoothing compensatory effect of
GnRH/LH are still unknown, but estrogens and insulin, as
well as leptin, TNF-𝛼, and other adipokines, were proposed
candidates [15, 27]. An alternative etiopathogenic explanation
for this phenomenon proposes that fat stores undertake
an increase aromatization of androgens, therefore raising
estrogen levels [9, 15], which in turn decrease LH secretion
[9]. Hence, aging being associatedwith an increase in adipose
tissue accretion, a link between age and hypogonadism was
established [32]. However, in opposition to mixed hypoan-
drogenism definition, our MetS patients did not evidence
changes in themedian LH levels compared to non-MetS ones.
This was also true when only the patients with hypogonadism
were considered, suggesting that other factors than MetS
and obesity, such as age or any of the molecules described
above, might have a stronger influence on the HPG axis. It is
likely that the underlying ED, a common feature of all of our
patients, might play a multi-factorial masking role. Although
possible unforeseen confounders might also be influencing
this relation, the greatest effortsweremade in order to exclude
patients with known underlying pathologies or comorbidities
that could influence the hormonal results.
Theoretically, our data contradicts the concept that estra-
diol exerts a negative feedback on hypothalamicGnRH secre-
tion [28], as it would not be expected to find raised estradiol
levels concomitant with raised LH levels. We hypothesize
that, in our group of patients with MetS that did not present
estrogenic HPG axis-attenuation effect, obesity is playing an
important role in the estradiol levels increase. Nevertheless,
we have just a few patients without an estrogenic HPG
axis-attenuation effect and, amongst them, there were not
enoughMetS cases to accurately test this hypothesis in aMetS
setting. On the other hand, when considering data from pati-
ents with an estrogenic HPG axis-attenuation effect but
without MetS, possible explanations may imply additional
molecules, age-related fat deposits, or other estrogen-raising
mechanisms. However, even in this setting, the absence of
estradiol effect on LH secretion is still puzzling. Thus, taking
into account that high estradiol levels have already been
described as the only abnormality in a subset of patients with
ED, the hypothesis that the later might not only be caused by
androgen deficiency is becoming increasingly evident [8, 20].
Furthermore, it has been reported that the chronic exposure
to phosphodiesterase type 5 inhibitors (PDE5i), widely used
for the treatment of ED, may influence serum estradiol levels
[33, 34]. Even though we did not evaluate the influence of
PDE5i on the hormonal axis, we cannot exclude the role
these drugs might have in the serum T : estradiol ratio of our
patients.
When expanding this analysis for a broader endocrino-
logical spectrum, one must consider that even though a very
limited number of cases of dysthyroidism were found in our
population, thyroid disorders (specially hyperthyroidism)
have been related to ED and hypogonadism, and so must be
considered in a sexual-dysfunction setting [21, 22]. It is clear
from the current literature that collecting a more thorough
hormonal panel might be a wise approach to further uncover
hormonal relations.
Our study has several limitations, one being its retrospec-
tive design. It is possible that some confounders have not
been traced, therefore influencing the results. Nevertheless,
a thorough analysis of the patients was made in order to exc-
lude underlying pathologies or comorbidities that could alter
the results. Moreover, the sample size was sometimes a limi-
ting factor to test some hypothesis.
We concluded that in ED patients with hypogonadism
and MetS, the attenuated response of HPG axis (normal
or low LH levels) might not always be due to an underly-
ing adiposity-dependent estrogen-raising effect. The lower
estradiol levels observed in this peculiar group of patients
suggest that they may be influenced by mechanisms that are
not yet unveiled. Similarly, the increased estradiol levels in
patients with hypogonadism and a normally responsive HPG
axis (raised LH levels), mainly when MetS is not present,
remain to be elucidated. In addition, the basis for estradiol
negative feedback mechanism on the hypothalamic GnRH
secretion and consequently on the HPG axis should be
further investigated to clarify the concomitant increase of LH
and estradiol. In themeantime, our findings indicate that ED,
aging, and estradiol might have a stronger connection than
what is currently described in the literature.
Overall, this study underlines the importance of the
collection of a full hormonal panel in ED men, as well as
a detailed clinical history, to exclude the presence of other
hormonal disturbances than hypogonadism and MetS. Our
results yield further insights into this still unclear multi-
disciplinary and complex subject and raise new research
opportunities on alternative factors mediating the relation-
ship between ED, hypogonadism, and MetS.
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